Tag: NPH
EShunt system receives US FDA Breakthrough Device designation for hydrocephalus treatment
Cerevasc has announced it has received Breakthrough Device designation from the US Food and Drug Administration (FDA) for its eShunt system, which is intended...
Cerevasc announces US FDA-approved expansion of normal-pressure hydrocephalus study
Cerevasc has announced that the US Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) supplement to permit the expansion of...
First patient treated in clinical trial of CereVasc’s eShunt system for...
CereVasc has announced treatment of the first patient in its clinical study of the eShunt system in patients with normal-pressure hydrocephalus (NPH).
Following approval from Argentina's...
